☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
AbbVie
AbbVie’s Tepkinly (Epcoritamab) Gains the CHMP’s Positive Opinion to Treat R/R Follicular Lymphoma
July 1, 2024
AbbVie Reports the Acquisition of Celsius Therapeutics
June 28, 2024
AbbVie’s Epkinly (epcoritamab-bysp) Receives the US FDA’s Accelerated Approval to Treat R/R Follicular Lymphoma
June 27, 2024
AbbVie Receives Complete Response Letter for ABBV-951's NDA to Treat Parkinson's Disease
June 26, 2024
AbbVie's Skyrizi Gains the US FDA’s Approval for Treating Ulcerative Colitis
June 19, 2024
AbbVie Teams Up FutureGen to Advance Next-Generation Therapy to Address Inflammatory Bowel Disease
June 14, 2024
Load more...
Back to Home